
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical is expected to demonstrate significant improvements in its financial performance, with projected EBITDA increasing from $23.3 million in FY26, reflecting a margin of 16.8%, to $27.3 million in FY27, indicating an expanding margin of 19.1%. Additionally, the company has achieved positive free cash flow, anticipated to rise from $5.1 million in FY26 to $6.0 million in FY27. This upward trend in both EBITDA and free cash flow points to a solid foundation for sustained growth and enhanced operational efficiency.
Bears say
Lifecore Biomedical Inc. faces a negative financial outlook primarily due to its high leverage ratio, which raises concerns about the company's financial stability and risk profile. Additionally, the projected revenue growth from its contract development and manufacturing operations is expected to be lackluster, with meaningful growth not anticipated until calendar year 2027. Furthermore, the anticipated market growth for fill/finish services may underperform expectations, further complicating Lifecore's competitive positioning compared to its peers.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares